SAN75.52-1.19%
SAN · CAC
1y range: 72.49 → 82.03 · as of 2026-08-14
AI digest — today
Sanofi blijft onder druk door €1,03 mld impairmentsverliezen in Q2, maar ondersteunt aandeelhouders met €1,01 mld buyback (1,05% aandelen). Positief: Novavax-partner meldde Q2-beat en verhoogde guidance, wat Sanofi's vaccin-portfolio versterkt.
Generated 2026-08-07 06:02
Weekly thesis
Dupixent-motor draait sterk (+37,6% Q2), maar impairmentsverliezen en vaccin-tegenwind temperen upside; swing traders wachten op duidelijkheid over post-2028 groei.
Bull case
- Dupixent +37,6% YoY naar €5,2B in Q2 2026; FDA-goedkeuring urticaria kinderen (2-11 jaar) breidt adresbare markt uit — runway tot minstens 2028 intact - Q2 2026 business EPS €2,09 met jaarlijkse guidance verhoogd; consistent beat-patroon (Q1 +31,1%, Q4 +13,9%) toont operationele discipline - Pharma-launches +48,3% in Q2; Novavax-partner beat Q2 en verhoogde guidance, wat Sanofi's vaccin-portfolio versterkt (tegenwind kan omslaan) - €1,01B buyback (1,05% aandelen) + 23 analisten op Buy = kapitaaldiscipline + consensus steun; geen Sell-ratings - Matrix-M adjuvant platform expansion en KT-621 Phase 2b atopic dermatitis enrollment 6 maanden eerder voltooid — pijplijn-momentum
Bear case
- €1,03B impairmentsverliezen op immateriële activa signaleren R&D-teleurstellingen; vorige thesis noemde 'structurele R&D-zwakte' — dit blijft onopgelost - Vaccins -4,7% in Q2; H1 2026 netto-omzet daalde ondanks Dupixent-groei — diversificatie-risico - Dupixent patent cliff ~2031; geen duidelijke post-2028 groeimotor benoemd in digests — 'harvest'-scenario risico - BNP Paribas downgrade naar Neutral (april 2026) signaleert 'unlikely near-term rerating' — momentum-risico voor swing traders op 1-6M horizon - Swing naar netto-schuld gemeld; impairmentsverliezen + buyback combinatie kan kasflow-flexibiliteit beperken als groei vertraagt
Recent material news
- Santander: Upswing On One Of My Best Banking "Bets" May Be Fizzling Out (Rating Downgrade)2026-08-13T10:57
- Novavax Q2 Earnings Call Highlights2026-08-07T06:04
- Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses2026-08-06T13:54
- Euroapi SA (EAPIF) (H1 2026) Earnings Call Highlights: Transformation Costs and Market ...2026-08-06T01:01
- Kymera Therapeutics Q2 Earnings Call Highlights2026-08-05T17:04
- Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...2026-08-05T05:05
- Is Sanofi (ENXTPA:SAN) Cheap On Impairments And A €1b Buyback?2026-08-01T18:09
- Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...2026-07-30T19:03
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.